首页> 美国卫生研究院文献>AAPS PharmSciTech >Development of Modified-Release Tablets of Zolpidem Tartrate by Biphasic Quick/Slow Delivery System
【2h】

Development of Modified-Release Tablets of Zolpidem Tartrate by Biphasic Quick/Slow Delivery System

机译:双相快速/慢速递送系统开发酒石酸唑吡坦片的缓释片

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Zolpidem tartrate is a non-benzodiazepine analogue of imidazopyridine of sedative and hypnotic category. It has a short half-life with usual dosage regimen being 5 mg, two times a day, or 10 mg, once daily. The duration of action is considered too short in certain circumstances. Thus, it is desirable to lengthen the duration of action. The formulation design was implemented by preparing extended-release tablets of zolpidem tartrate using the biphasic delivery system technology, where sodium starch glycolate acts as a superdisintegrant in immediate-release part and hydroxypropyl methyl cellulose as a release retarding agent in extended-release core. Tablets were prepared by direct compression. Both the core and the coat contained the drug. The pre-compression blends were evaluated for angle of repose, bulk density, and compressibility index. The tablets were evaluated for thickness, hardness, weight variation test, friability, and in vitro release studies. No interaction was observed between zolpidem tartrate and excipients from the Fourier transform infrared spectroscopy and differential scanning calorimetry analysis. The results of all the formulations prepared were compared with reference product Stilnoct®. Optimized formulations showed release patterns that match the United States Pharmacopeia (USP) guidelines for zolpidem tartrate extended-release tablets. The mechanism of drug release was studied using different mathematical models, and the optimized formulation has shown Fickian diffusion. Accelerated stability studies were performed on the optimized formulation.
机译:酒石酸唑吡坦是镇静和催眠类咪唑并吡啶的非苯并二氮杂pine类似物。它的半衰期短,通常的剂量为5 mg,每天两次,或10 mg,每天一次。在某些情况下,作用时间被认为太短。因此,期望延长作用时间。通过使用双相递送系统技术制备酒石酸唑吡坦的缓释片剂来实现配方设计,其中羟乙酸淀粉钠在速释部分中充当超崩解剂,而羟丙基甲基纤维素在缓释核心中充当缓释剂。通过直接压制制备片剂。药芯和皮都含有药物。评估预压缩共混物的休止角,堆积密度和可压缩性指数。评价片剂的厚度,硬度,重量变化测试,易碎性和体外释放研究。酒石酸唑吡坦与赋形剂的傅里叶变换红外光谱法和差示扫描量热法分析未见相互作用。将所制备的所有制剂的结果与参考产品Stilnoct®进行比较。优化的制剂显示出与美国药典(USP)酒石酸唑吡坦缓释片指南相匹配的释放模式。使用不同的数学模型研究了药物释放的机制,并且优化的配方显示出Fickian扩散。对优化配方进行了加速稳定性研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号